Silence Therapeutics Plc (SLNCF)
3.85
0.00 (0.00%)
USD |
OTCM |
Oct 15, 16:00
Silence Therapeutics Cash from Operations (TTM) : -41.79M for June 30, 2026
Cash from Operations (TTM) Chart
Historical Cash from Operations (TTM) Data
| Date | Value |
|---|---|
| June 30, 2026 | -41.79M |
| March 31, 2026 | -66.13M |
| December 31, 2025 | -62.84M |
| September 30, 2025 | -71.13M |
| June 30, 2025 | -65.35M |
| March 31, 2025 | -51.70M |
| September 30, 2024 | -53.64M |
| Date | Value |
|---|---|
| June 30, 2024 | -34.16M |
| March 31, 2024 | -47.75M |
| December 31, 2023 | -47.72M |
| September 30, 2023 | -49.18M |
| June 30, 2023 | -54.75M |
| March 31, 2023 | -46.23M |
| December 31, 2022 | -56.40M |
Cash From Operations Definition
Represents the net cash flow from the company's business operations.
Cash from Operations (TTM) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Operations (TTM) Benchmarks
| Biodexa Pharmaceuticals Plc | -9.219M |
| NuCana Plc | -6.332M |
| Mereo BioPharma Group Plc | -25.28M |
| Compass Pathways Plc | -160.76M |
| HemoGenyx Pharmaceuticals Plc | -1.937M |